pharma · Critical Limb Ischemia (CLI) · Sarcoma · DSGN
Lxo Ireland Designated
Lxo Ireland Designated Activity Company
Lxo Ireland Designated is a pharma organization headquartered in CARLSBAD, CA, IE. It trades on NYSE under ticker DSGN. Primary therapeutic focus areas include Critical Limb Ischemia (CLI), Sarcoma, Friedreich Ataxia, HP
CARLSBAD, CA, IE HQ
Public company Type
DSGN · NYSE Ticker
Company details
- Status
- Public
- HQ
- CARLSBAD, CA, IE
- Programs
- 68
- Drugs
- 61
- Patents
- 201
DT-168
Phase 2 · small molecule · Fuchs Endothelial Corneal Dystrophy
DT-168 for Fuchs Endothelial Corneal Dystrophy is a Phase 2 program (small_molecule) at Lxo Ireland Designated Activity Company with 1 ClinicalTrials.gov record(s).
Internal code DTX-168-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Lxo Ireland Designated Activity Company
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Fuchs Endothelial Corneal Dystrophy
- Status
- active
- Trials
- 1